Duan Xiaohong, Xing Zhiyao, Qiao Lu, Qin Shan, Zhao Xuejing, Gong Yanhua, Li Xueren
School of Disaster and Emergency Medicine, Faculty of Medicine, Tianjin University, Tianjin, China.
Institute of Disaster and Emergency Medicine, Faculty of Medicine, Tianjin University, Tianjin, China.
Front Immunol. 2024 Nov 15;15:1495221. doi: 10.3389/fimmu.2024.1495221. eCollection 2024.
Histones play crucial roles in both promoting and repressing gene expression, primarily regulated through post-translational modifications (PTMs) at specific amino acid residues. Histone PTMs, including methylation, acetylation, ubiquitination, phosphorylation, lactylation, butyrylation, and propionylation, act as important epigenetic markers. These modifications influence not only chromatin compaction but also gene expression. Their importance extends to the treatment and prevention of various human diseases, particularly cancer, due to their involvement in key cellular processes. Abnormal histone modifications and the enzymes responsible for these alterations often serve as critical drivers in tumor cell proliferation, invasion, apoptosis, and stemness. This review introduces key histone PTMs and the enzymes responsible for these modifications, examining their impact on tumorigenesis and cancer progression. Furthermore, it explores therapeutic strategies targeting histone PTMs and offers recommendations for identifying new potential therapeutic targets.
组蛋白在促进和抑制基因表达方面都起着至关重要的作用,主要通过特定氨基酸残基的翻译后修饰(PTMs)来调节。组蛋白PTMs,包括甲基化、乙酰化、泛素化、磷酸化、乳酰化、丁酰化和丙酰化,作为重要的表观遗传标记。这些修饰不仅影响染色质的紧实度,还影响基因表达。由于它们参与关键的细胞过程,其重要性延伸到各种人类疾病的治疗和预防,特别是癌症。异常的组蛋白修饰以及负责这些改变的酶通常是肿瘤细胞增殖、侵袭、凋亡和干性的关键驱动因素。本综述介绍了关键的组蛋白PTMs以及负责这些修饰的酶,研究了它们对肿瘤发生和癌症进展的影响。此外,还探讨了针对组蛋白PTMs的治疗策略,并为确定新的潜在治疗靶点提供了建议。
Cell Mol Biol (Noisy-le-grand). 2015-10-30
Clin Epigenetics. 2025-2-20
Signal Transduct Target Ther. 2024-9-16
Invest New Drugs. 2025-8-21
Pharmaceuticals (Basel). 2025-6-26
Biomolecules. 2025-7-18
Oncol Lett. 2025-7-2
Cell Rep Med. 2024-3-19
Cancer Res Commun. 2024-2-13
Cancer Immunol Immunother. 2024-1-17